DUBLIN--(BUSINESS WIRE)--The "Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.
Chronic Kidney Disease Market: Pipeline Review, Developer Landscape, and Competitive Insights provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of chronic kidney disease.
Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition.
In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD. In fact, the mean global prevalence of CKD, across all five stages of the disease, is estimated to be 13.4%.
Limited availability of epidemiological data, lack of awareness, late diagnosis and inappropriate/incorrect treatment are some of the factors responsible for elevating disease incidence. It is also worth noting that developed nations spend over 2-3% of their annual healthcare budget on the treatment of end-stage renal disease (ESRD); however, the economic burden associated with milder forms of CKD is almost double the total costs incurred in the treatment of ESRD.
Further, in the US, the disease has been estimated to incur combined direct and indirect costs ranging between USD 1,183 - USD 35,292 per patient, per month.
Existing therapeutic options have already been proven to be inadequate in containing the progression of the disease and its symptoms in the long term.
Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease-modifying pharmacological interventions and therapies that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital funding in order to expedite the development of potential therapeutic options for better disease management.
Key Topics Covered
2. Executive Summary
4. Pipeline Review: Marketed And Development Drugs
5. Product Clinical Commercial Attractiveness
6. Chronic Kidney Disease: Unmet Needs Analysis
7. Company Competitiveness Analysis
8. KOL Analysis
9. Partnerships and Collaborations
10. Funding & Investment Analysis
- Aarhus University
- Achillion Pharmaceuticals
- Amyndas Pharmaceuticals
- Angion Biomedica
- Anthera Pharmaceuticals
- Apellis Pharmaceuticals
- Apollo Hospitals
- AptaBio Therapeutics
- Dong-A ST
- Dongguk University
- Duke University
- Dynavax Technologies
- Eastern Capital
- F-Prime Capital Partners
- Flagship Pioneering
- Georgetown University
- Gilead Sciences
- Hamad Medical
- KAI Pharmaceuticals
- Orbis Biosciences
- Sahlgrenska University Hospital
- Samsung Medical Center
- St. George's University
- XORTX Therapeutics
- Yuhan Corporation
- Zeria Pharmaceutical
- ZS Pharma
- and many more...
For more information about this report visit https://www.researchandmarkets.com/research/d9lvmh/chronic_kidney?w=4